Janus kinase 3

From WikiMD's Medical Encyclopedia

Revision as of 09:12, 19 March 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Janus kinase 3 (JAK3) is a protein that in humans is encoded by the JAK3 gene. It is a member of the Janus kinase family and plays a critical role in the JAK-STAT signaling pathway, which is involved in the control of cell growth, cell differentiation, and immune system function. JAK3 specifically is essential for the signaling of cytokines that bind to the Type I and Type III receptor families.

Function

JAK3 is predominantly expressed in immune cells, including T cells, B cells, and natural killer cells. It is involved in the signaling pathway of cytokines such as interleukin-2, interleukin-4, interleukin-7, interleukin-9, interleukin-15, and interleukin-21, which are crucial for lymphocyte development, function, and homeostasis. Activation of JAK3 leads to the phosphorylation and activation of STATs (Signal Transducers and Activators of Transcription), which then translocate to the nucleus to effect gene expression.

Clinical Significance

Mutations in the JAK3 gene can lead to immunodeficiency syndromes, including severe combined immunodeficiency (SCID). Patients with JAK3-deficient SCID exhibit a lack of T cells and NK cells, while B cells are present but functionally impaired. This condition is characterized by a severe impairment in both cellular and humoral immunity, leading to a high susceptibility to infections.

In addition to its role in immunodeficiency, JAK3 is a target for drug discovery due to its involvement in various autoimmune diseases and cancers. Inhibitors of JAK3, such as tofacitinib, are being developed and used in the treatment of conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis.

Inhibitors

Several small molecule inhibitors targeting JAK3 have been identified and are in various stages of development and clinical trials for the treatment of autoimmune diseases and cancers. These inhibitors work by blocking the kinase activity of JAK3, thereby interrupting the JAK-STAT signaling pathway and reducing the inflammatory and proliferative responses.

See Also

References

<references />

Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.